Loading...
XNAS
SYRS
Market cap673kUSD
Jun 04, Last price  
0.03USD
1D
-2.90%
1Q
-70.54%
Jan 2017
-99.98%
IPO
-99.99%
Name

Syros Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
54.04%
Rev. gr., 5y
37.12%
Revenues
10m
-33.23%
00317,000317,0001,101,0002,050,0001,982,00015,093,00023,488,00014,880,0009,936,000
Net income
-165m
L+233.81%
-9,259,000-13,431,000-29,818,000-47,743,000-54,010,000-62,279,000-75,438,000-85,830,000-90,465,000-49,301,000-164,574,000
CFO
-110m
L-10.85%
-7,194,000-11,969,000-23,030,000-40,536,000-44,729,000-40,315,000-60,253,000-57,364,000-99,540,000-123,065,000-109,707,000
Earnings
Jul 29, 2025

Profile

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
URL
https://syros.com/
IPO date
Jun 30, 2016
Employees
117
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,936
-33.23%
14,880
-36.65%
Cost of revenue
138,687
144,210
Unusual Expense (Income)
NOPBT
(128,751)
(129,330)
NOPBT Margin
Operating Taxes
(45,353)
Tax Rate
NOPAT
(128,751)
(83,977)
Net income
(164,574)
233.81%
(49,301)
-45.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
43,270
119,978
BB yield
-19.61%
-264.57%
Debt
Debt current
11,315
2,071
Long-term debt
73,936
84,422
Deferred revenue
Other long-term liabilities
61,747
24,472
Net debt
(54,275)
(118,897)
Cash flow
Cash from operating activities
(109,707)
(123,065)
CAPEX
(272)
(1,241)
Cash from investing activities
37,337
67,185
Cash from financing activities
43,462
131,045
FCF
(123,574)
(81,352)
Balance
Cash
139,526
202,304
Long term investments
3,086
Excess cash
139,029
204,646
Stockholders' equity
(722,781)
(558,111)
Invested Capital
865,589
773,890
ROIC
ROCE
EV
Common stock shares outstanding
28,326
12,632
Price
7.79
116.99%
3.59
-88.99%
Market cap
220,658
386.58%
45,349
-77.76%
EV
166,383
(73,548)
EBITDA
(126,499)
(126,363)
EV/EBITDA
0.58
Interest
5,127
4,134
Interest/NOPBT